242 related articles for article (PubMed ID: 33496740)
1. DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.
Kayamori K; Nagai Y; Zhong C; Kaito S; Shinoda D; Koide S; Kuribayashi W; Oshima M; Nakajima-Takagi Y; Yamashita M; Mimura N; Becker HJ; Izawa K; Yamazaki S; Iwano S; Miyawaki A; Ito R; Tohyama K; Lennox W; Sheedy J; Weetall M; Sakaida E; Yokote K; Iwama A
Blood Adv; 2021 Jan; 5(2):438-450. PubMed ID: 33496740
[TBL] [Abstract][Full Text] [Related]
2. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Cao L; Weetall M; Trotta C; Cintron K; Ma J; Kim MJ; Furia B; Romfo C; Graci JD; Li W; Du J; Sheedy J; Hedrick J; Risher N; Yeh S; Qi H; Arasu T; Hwang S; Lennox W; Kong R; Petruska J; Moon YC; Babiak J; Davis TW; Jacobson A; Almstead NG; Branstrom A; Colacino JM; Peltz SW
Mol Cancer Ther; 2019 Jan; 18(1):3-16. PubMed ID: 30352802
[TBL] [Abstract][Full Text] [Related]
3. AICAR suppresses cell proliferation and synergizes with decitabine in myelodysplastic syndrome via DNA damage induction.
Liu J; Liang L; Li X; Peng YL; Zhang J; Wang XL; Liu J; Nie L
Biotechnol Lett; 2021 Jun; 43(6):1131-1142. PubMed ID: 33788127
[TBL] [Abstract][Full Text] [Related]
4. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines.
Luban J; Sattler RA; Mühlberger E; Graci JD; Cao L; Weetall M; Trotta C; Colacino JM; Bavari S; Strambio-De-Castillia C; Suder EL; Wang Y; Soloveva V; Cintron-Lue K; Naryshkin NA; Pykett M; Welch EM; O'Keefe K; Kong R; Goodwin E; Jacobson A; Paessler S; Peltz SW
Virus Res; 2021 Jan; 292():198246. PubMed ID: 33249060
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.
Zhong C; Kayamori K; Koide S; Shinoda D; Oshima M; Nakajima-Takagi Y; Nagai Y; Mimura N; Sakaida E; Yamazaki S; Iwano S; Miyawaki A; Ito R; Tohyama K; Yamaguchi K; Furukawa Y; Lennox W; Sheedy J; Weetall M; Iwama A
Cancer Sci; 2020 Dec; 111(12):4336-4347. PubMed ID: 33037737
[TBL] [Abstract][Full Text] [Related]
6. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC
Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990
[TBL] [Abstract][Full Text] [Related]
7. The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines.
Luban J; Sattler R; Mühlberger E; Graci JD; Cao L; Weetall M; Trotta C; Colacino JM; Bavari S; Strambio-De-Castillia C; Suder EL; Wang Y; Soloveva V; Cintron-Lue K; Naryshkin NA; Pykett M; Welch EM; O'Keefe K; Kong R; Goodwin E; Jacobson A; Paessler S; Peltz S
bioRxiv; 2020 Aug; ():. PubMed ID: 32793904
[TBL] [Abstract][Full Text] [Related]
8. Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
Branstrom A; Cao L; Furia B; Trotta C; Santaguida M; Graci JD; Colacino JM; Ray B; Li W; Sheedy J; Mollin A; Yeh S; Kong R; Sheridan R; Baird JD; O'Keefe K; Spiegel R; Goodwin E; Keating S; Weetall M
Front Oncol; 2022; 12():832816. PubMed ID: 35223511
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
10. Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms.
Tamura M; Yonezawa T; Liu X; Asada S; Hayashi Y; Fukuyama T; Tanaka Y; Kitamura T; Goyama S
Sci Rep; 2019 Jun; 9(1):8171. PubMed ID: 31160638
[TBL] [Abstract][Full Text] [Related]
11. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
Huang L; Liu Z; Jiang H; Li L; Fu R
J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
[TBL] [Abstract][Full Text] [Related]
12. Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes.
Kim S; Shin DY; Kim D; Oh S; Hong J; Kim I; Kim E
Cells; 2021 Dec; 10(12):. PubMed ID: 34944006
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
14. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
15. Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs; 2020 Sep; 80(13):1373-1378. PubMed ID: 32860582
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
17. The role of decitabine in the treatment of myelodysplastic syndromes.
Atallah E; Kantarjian H; Garcia-Manero G
Expert Opin Pharmacother; 2007 Jan; 8(1):65-73. PubMed ID: 17163808
[TBL] [Abstract][Full Text] [Related]
18. [Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
Klepfish A; Silbershatz I; Lugassy G; Shimoni A; Mittelman M
Harefuah; 2013 Oct; 152(10):591-4, 624. PubMed ID: 24450031
[TBL] [Abstract][Full Text] [Related]
19. [Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
Yang H; Zhu HY; Jiang MM; Wang QS; Han XP; Huang WR; Jing Y; Wang SH; Zhang SS; Mei JH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):121-5. PubMed ID: 23484704
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]